BTIG analyst Ryan Zimmerman downgraded Staar Surgical to Neutral from Buy without a price target. The analyst says the company is "wed to China and investors are subsequently wed to the undulations of the Chinese economy." Implied in Staar’s fiscal 2023 revenue guidance of $340M are meaningful step-ups in productivity in the company’s physician base the analyst tells investors in a research note. The firm believes these increases are likely to prove challenging and says Staar would have to increase market penetration by hundreds, if not a thousand, basis points to meet its outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
- Staar Surgical price target raised to $80 from $79 at Canaccord
- Staar Surgical price target raised to $79 from $76 at Canaccord
- Staar Surgical reports preliminary Q4 revenue $64M, consensus $65.01M
- This Insider Just Bought Staar Surgical (NASDAQ:STAA) Shares Worth $9.1M
- Staar Surgical price target lowered to $67 from $80 at BTIG